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Abstract 
Background: Current treatment options for end-stage heart failure, such as 
transplantation, can be limited by obesity guidelines. Mechanical devices such as 
Left Ventricular Assistive Devices (LVAD) can bridge heart failure patients to 
transplantation, however, after implantation; some patients may experience weight 
gain that precludes them from transplantation. Therefore, the objective of this 
study was to evaluate weight changes after the implantation of an LVAD. 
Methods: A retrospective review of 130 patients receiving an LVAD were divided 
into two groups based on BMI at the time of implantation: obese (>30 kg/m2) and 
non-obese (/m2). Patients were evaluated at three time points post LVAD 
implantation: 3, 6, and 12 months for changes in weight and BMI. 
Results: The mean BMI of the overall cohort at the time of LVAD implantation was 
30.3 kg/m2. Patients who were not classified as obese at the time of LVAD 
implementation had a significant increase in BMI (2.1 kg/m2, p<0.001). 
Conclusion: Weight gain after LVAD implementation is more likely in patients who 
are non-obese at the time of LVAD evaluation; however, obese subjects remained 
unlikely to lose weight one year post implantation. 
Keywords 
Heart failure, obesity, BMI, weight, cardiac transplantation, ventricular assist 
device, LVAD 
 
 
Citation: Thomas, R. et al.(2016).  
" Exploring Body Mass Index 
Changes in Left Ventricular 
Assist Device Patients” 
The VAD Journal, 2. doi:  
http://dx.doi.org/10.13023/VAD.2
016.13 
 
Editor-in-Chief: Maya Guglin, 
University of Kentucky 
Received: April 14, 2016 
Accepted: June 8, 2016 
Published: June 8, 2016 
© 2016 The Author(s).  This is an 
open access article published 
under the terms of the Creative 
Commons Attribution-
NonCommercial 4.0 International 
License 
(https://creativecommons.org/lice
nses/by-nc/4.0/), which permits 
unrestricted non-commercial use, 
distribution, and reproduction in 
any medium, provided that the 
original author(s) and the 
publication source are credited.   
Funding: Not applicable  
Competing interests: Not 
applicable 
 
  
 
 
The VAD Journal: http://dx.doi.org/10.13023/VAD.2016.13 Page 2 of 11 
 
The VAD Journal: The journal of mechanical assisted circulation and heart failure 
Introduction 
 
Heart failure affects a reported 5.1 million Americans.1 Despite advancements in 
medicine; a diagnosis of heart failure continues to have a poor prognosis. 
Likewise, obesity is a growing problem in the United States and is also an 
independent risk factor for the development of heart failure.2-4 Obese patients are 
twice as likely to develop heart failure when compared to their non-obese 
counterparts,4  and obesity limits available treatment options in those with heart 
failure. Mechanical assist devices, such as Left Ventricular Assist Devices (LVAD), 
offer an alternative option to prolong life or bridge patients to cardiac 
transplantation. Obesity alone is not contraindicated for LVAD placement; 
however, transplantation guidelines for mechanical circulatory support encourage 
thoughtful considerations for surgical risk and comorbidities before implanting the 
morbidly obese patient.5   
After LVAD implantation, some patients can experience weight gain that may 
exclude them from transplantation, and many implanted obese patients fail to lose 
weight in order to meet BMI listing criteria for transplant.6-8 However, very little is 
known about the patterns of weight gain in patients after LVAD implantation. 
Therefore, the purpose of this study is to explore BMI changes in the post-LVAD 
population. 
Patients and Methods 
Participants and Study design  
Prior to data collection, Institutional Review Board approval was obtained for a 
retrospective analysis of patients who qualified for LVAD implantation from 2009-
2014. Adult participants over 19 years of age implanted with the Heartmate II 
device were eligible for enrollment. Patients who had a survival of less than 90 
days post-implant were excluded.  
Electronic medical records were used to retrospectively collect clinical, 
demographic and anthropometric data for patients implanted between January 
2009 and December 2014.   
Data Collection 
Body mass index (BMI) of participants was collected at designated intervals, 
including time of LVAD evaluation and routine follow-up clinic visits or 
hospitalizations at the 3-, 6- and 12-month markers. BMI was chosen as a primary 
outcome as it is a standard measure used in transplant selection. Participants 
were categorized by BMI as defined by the World Health Organization at the time 
of evaluation: underweight (BMI <18.5kg/m2), normal (BMI 18.5-24.9 kg/m2), 
overweight (BMI 25-29.9 kg/m2) and obese (BMI >30 kg/m2).9  
Additional baseline data was collected from the participants at their initial 
evaluation for LVAD and from routine follow-up clinic visits or hospitalizations at 
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the 3-, 6-, and 12-month intervals for comparison of BMI changes over time. 
Demographic data, classification of heart failure, severity of illness, psychosocial 
factors, and lab data represented the clinical characteristics. Demographic data 
collected includes subject’s gender and age. Classification of heart failure and 
severity of illness were evaluated by obtaining information on ejection fraction, 
etiology of heart failure, ICU length of stay on implant, readmissions to hospital 
and implant strategy. Lab data included hemoglobin A1C, B-type natriuretic 
peptide (BNP), prealbumin, serum sodium, serum osmolality, serum creatinine, 
and total bilirubin.  
Data was also collected on the utilization of bariatric referral over time and diuretic 
use.  
Data Analysis  
Descriptive statistics were calculated for all variables. Continuous data were 
represented as mean and standard deviation. Categorical data were expressed as 
counts and percentages. Changes between BMI at each time point were 
compared using either the paired t-test for normal data or the Wilcoxon signed 
rank test for non-normal data.  
The demographic and clinical characteristics of the participants were compared 
between the non-obese and obese groups using the independent sample t-test 
and Wilcoxon rank-sum for continuous data, and the Chi-square test or Fisher’s 
exact test for categorical data, as appropriate. 
 
All statistical analysis was performed using IBM SPSS Statistics 22. Statistical 
significance was measured at a p-value < 0.05. 
 
Results 
The final number of participants in the study was 130, with a total of 103 males 
(79%) and 27 (21%) females. The mean BMI of the overall cohort at the time of 
LVAD implant was 30.3 kg/m2. Over 80% of participants were considered 
overweight (BMI of 25-29.9 kg/m2) or obese (>30 kg/m2) (30% vs 51.5%, 
respectively). ). Only one participant was categorized as underweight and less 
than 20% of the entire cohort was considered to be in the underweight or normal 
weight categories. Because of this distribution among the four BMI groups, 
patients were then collapsed into two BMI groups; obese (BMI >30.0kg/m2) and 
non-obese (BMI <29.9 kg/m2). Within these categories, 51.5% of the population 
was considered obese (BMI >30kg/m2) with 48.5% classified as non-obese (<29.9 
kg/m2). Clinical characteristics for all participants observed at time of implant are 
presented in Table 1. 
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Table 1: Clinical Characteristics on Implant 
Variables (N) 
BMI Groups 
Non- Obese 
(N=63) 
Obese (N=67) 
N Mean (S.D.) N Mean (S. D.) 
P 
value 
Age, years (130) 63 57.6 (13.2) 67 54.0 (12.4) 0.11 
Initial BMI, kg/m2 (130) 63 25.2 (2.9) 67 35.1 (4.0) <0.001 
3 Month BMI, kg/m2  (124) 60 25.2 (2.8) 64 33.8 (4.3) <0.001 
6 Month BMI, kg/m2  (90) 43 26.5 (3.6) 47 34.9 (4.9) <0.001 
12 Month BMI, kg/m2  (49) 22 27.8 (3.0) 27 36.1 (4.7) <0.001 
A1C, % (120) 58 6.5 (1.4) 61 6.9 (1.4) 0.22 
Prealbumin, mg/dL (122) 59 20.2 (8.3) 63 21.6 (7.9) 0.33 
Initial Sodium, mmol/L (130) 63 135.8 (4.0) 67 136.2 (3.3) 0.59 
Initial Osmolality, mOsm/kg 
(130) 
63 280.0 (10.3) 67 282.0 (8.1) 0.21 
Initial Creatinine, mg/dL  (130) 63 1.3 (0.4) 67 1.3 (0.4) 0.88 
Initial Total Bili, mg/dL  (130) 63 1.8 (1.6) 67 1.4 (0.9) 0.08 
Initial BNP, pg/dL  (119) 
56 
1143.7 
(794.5) 
62 623.5 (617.0) <0.001 
Initial EF, % (130) 63 14.2 (6.3) 66 15.5 (6.8) 0.26 
ICU Length of Stay, days (78) 37 10.0 (6.3) 41 9.2 (7.6) 0.64 
Days Implanted, days (130) 63 357.8 (267.0) 67 381.7 (273.6) 0.62 
Readmit at 3 months, # (126) 62 0.5 (0.8) 64 0.6 (0.8) 0.75 
  
A diagnosis of diabetes (p= 0.03) and BNP levels (p= <0.001) were significantly 
different between the obese and non-obese groups. As expected the obese group 
had more diabetics; however, there was no significant difference when comparing 
hemoglobin A1C levels (non-obese 6.5% vs. obese 6.9%, p=0.22).  Bariatric 
referral was noted to be different among groups, which was to be expected. 
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The non-obese group had no significant BMI change between initial and 3 months 
measurement (p=0.787); however, they did show significant gains between initial 
BMI and 6 months as well as initial and 12 months measurement (1.4 kg/m2, 
p=<0.001; and 2.1 kg/m2, p=<0.001; respectively).  The obese group showed 
significant weight loss in the initial to 3 month mark, where the non-obese group 
did not (1.3 kg/m2+2.6, p=<0.001 and 0.06 kg/m2+1.8, p=0.787; respectively). The 
obese groups showed no change from initial BMI (35.1 kg/m2) at either the 6 
month (34.9 kg/m2, p=0.924) or the 12 month mark (36.1 kg/m2, p=0.359). These 
results are shown in Table 2.  
Table 2: BMI Changes Over Time* 
 BMI Groups 
 Non- Obese (N=63) Obese (N=67) 
Time (N) N Mean (S. D.) N Mean (S. D.) 
Initial BMI  (130) 63 25.2 (2.9) 67 35.1 (4.0) 
3 months (124) 60 25.2 (2.8) 64 33.8 (4.3) 
6 months (90) 43 26.5 (3.6) 47 34.9 (4.9) 
12 months (49) 22 27.8 (3.0) 27 36.1 (4.7) 
Change Over Time  
  
P 
value 
  P value 
Initial – 3 months 60 -0.1 (1.8) 0.787 64 -1.3 (2.6) <0.001 
Initial – 6 months 43 1.4 (2.3) <0.001 47 -0.1 (3.3) 0.924 
Initial – 12 months 22 2.1 (1.8) <0.001 27 0.6 (3.0) 0.359 
       
3 months - 6 months (90) 43 1.4 (1.9) <0.001 47 1.2 (1.5) <0.001 
6 months - 12 months 
(49) 
22 0.8 (2.0) 0.66 27 0.7 (0.4) 0.125 
       
3 months - 12 months 
(49) 
22 2.5 (1.6) <0.001 27 2.0 (2.8) 0.001 
*P value by Chi-Square test 
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Interestingly, both non-obese and obese groups showed increases in BMI between 
the 3 to 6 month marks (1.4 kg/m2, p=<0.001 and 1.2 kg/m2, p=<0.001; 
respectively) and even larger, more significant BMI gains between the 3 and 12 
month marks (2.5 kg/m2+1.6, p=<0.001 and 2.0 kg/m2+2.8, p=0.001; respectively). 
These BMI changes over time are displayed in Figure 1. 
  Figure 1:  BMI Change Over Time 
  
    Time 
Discussion 
Several studies show weight gain over time in the post-LVAD patient.6-8, 10 
However, our study shows that this BMI gain was more likely to occur in patients 
who are non-obese at the time of LVAD evaluation. These findings can be used to 
guide clinical practice and design more effective weight management strategies for 
post-LVAD patients and aid in preparing this patient population for cardiac 
transplantation.  
Some evidence shows a protective and beneficial effect in the overweight and 
obese populations after an established diagnosis of heart failure, described as the 
“obesity paradox”.15-17  This idea has shown that elevated BMI can have a 
protective effect and better outcomes in those who have been diagnosed with 
heart failure.  Considering the obesity paradox and the “U”-shaped curve among 
BMI groups, some may consider it beneficial for the non-obese group to gain 
weight.  However, a study by Guisado Rasco et al. shows adverse outcomes in 
both graft failure and mortality in post-transplant patients with a BMI >25kg/m2.18 In 
our study the BMI gain over time is concerning even among our non-obese group 
as the mean BMI for this group was 25.2 kg/m2 and after 1 year over 40% of the 
non-obese participants had a clinically significant BMI gain that increased the 
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average BMI to 27.8 kg/m2. These significant weight gains can necessitate 
changes to a patients’ transplant listing weight and need for careful consideration. 
As might be expected, the largest BMI gains were from the 3 to 12 month mark. 
Although our results did not show BMI gains that would exclude non-obese 
patients from transplantation, these changes are especially concerning as the 
average implant time for both the non-obese and obese were essentially 1 year 
(357.8+267 days vs 381.7+273.6 days; p=0.62, respectively). As previously shown 
in Figure 1, the trend of increasing BMI in the non-obese did not plateau over time 
and if followed further may interfere with eligibility for transplantation.  
Similar to our findings, a study by Emani et al. found that over the course of 24 
months, obese and extremely obese patients post-LVAD implant showed no 
significant change in BMI.6 Our study results are comparable in the obese group 
as they showed no significant total change from implant to 12 months; however, 
these results remain disheartening for this population to bridge to transplantation 
as guidelines recommend a BMI of <30kg/m2 to qualify for heart transplantation.11 
Thus, obesity complicates the decision regarding eligibility for heart 
transplantation. The prevalence of obesity in this population is further 
demonstrated by the overall BMI of our cohort at implantation; which, at 30.3kg/m2 
is above the suggested guidelines for heart transplantation. With more than 50% of 
the patients in this study being obese at the time of implantation and an increase in 
BMI over time in the patients that were not obese, transplant options can become 
limited even after LVAD implantation.  
Although the focus of this study was weight gain, weight loss was also evaluated. 
Initial weight loss post-surgery has been reported in other studies,6-8 most likely 
due to lack of appetite, increased nutritional needs during the peri-operative period 
and the type of mechanical device implanted.6,12-14 Interestingly, despite having the 
same device our obese group had significant weight loss (p=<0.001) whereas the 
non-obese group did not. This could be attributed to poor nutrition status and poor 
intake being frequently overlooked in the obese population, resulting in less 
nutrition interventions focusing on maintaining oral intake. 
As expected, diabetes was more common among the obese group. However, 
glucose control between groups at evaluation was not a contributing factor 
(p=0.22). Although the obese group had significantly more diabetic participants, 
hemoglobin A1C levels appeared to show good glucose control prior to LVAD 
implant. 
B-type natriuretic peptide (BNP) is “a neurohormone secreted mainly in the cardiac 
ventricles in response to volume expansion and pressure overload”.19 BNP is often 
considered a marker of disease progression in heart failure patients, with lower 
levels associated with less advanced disease. This is another aspect of the study 
that was congruent with previous research.2,20 Our study found lower BNP levels 
among the obese population as compared to the non-obese population 
(p=<0.001). Das et al. reported that higher BMI was independently associated with 
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lower BNP levels (p=<0.001).21 Another study by Daniels et al. showed similar 
results with lower BNP levels among the obese. Their study also suggests that for 
patients with a BMI >35kg/m2 a lower cut-point of BNP (≥54 pg/mL) should be 
used to maintain a high level of sensitivity. If not, they suggest that >1 in 5 obese 
patients with CHF symptoms may have a missed diagnosis with a BNP level <100 
pg/mL.22 Our obese group certainly would have met this criteria as the mean BNP 
level was 623.5pg/dL; however, this information may be very useful in earlier 
diagnosis, identification and treatment of heart failure among the obese population. 
With an increasing number of LVAD implants and limited options for treatment in 
the obese population, weight loss interventions are of importance. Research is 
limited on specific recommendations for weight loss among the heart failure and 
LVAD populations.23 However, one study involving LVAD patients shows a positive 
effect of nutrition counseling by a registered dietitian. Over the course of 18-
months the intervention group maintained their normal BMI as opposed to the 
control group that had a significant BMI gain (T1: 24.0+0.6 kg/m2 vs. T4: 24.5+1.1 
kg/m2, p=0.35 and T1: 23.8+0.6 kg/m2 vs. T4: 29.7+0.8 kg/m2, p=0.05; 
respectively).10 Newer studies have looked at the benefits and success of bariatric 
surgery.24-26 Although results sound promising, this option is not without substantial 
risk and potential complications even upon transplant as certain bariatric surgeries 
can cause absorptive issues with post-transplant immunosuppressant 
medications.24 
The nature of retrospective data collection contributes to the limitations of this 
study. Similarly, throughout the course of this study there was missing data due to 
participants being transplanted, expiring, or lost to follow up. Another limitation is 
that the vast majority of the patients in this particular study were overweight and 
obese. A larger study with a more equal distribution of BMI groups would provide 
more insight into patterns of weight change in this population. Lastly, given the 
relatively small sample size some p values for weight changes were not 
statistically significant. 
A registered dietitian (RD) plays a key role in the management of dietary and 
lifestyle modification. Dietary modification can help patients slow, maintain or lose 
weight to minimize risk of LVAD complications and contribute to goals for 
transplantation.  As seen in our study, prevention of weight gain in non-obese 
patients is key. Additionally, long-term individual counseling by a RD may 
contribute to fewer weight gains in the post-LVAD patient.10 In the obese 
population, identification and early weight management interventions may 
contribute to lower rebound weight gains after the three-month mark and a RD 
could provide additional resources for weight loss options. For the morbidly obese 
(BMI >35 kg/m2), perhaps an early referral to bariatric surgery is the best option for 
these patients to succeed with weight loss and bridge to transplantation.24-26 
Our study reports finding that significant BMI gain is limited to patients in the non-
obese group at the time of LVAD evaluation. We also provide supporting evidence 
that obese patients are unlikely to lose weight after one-year post LVAD implant.  
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